Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Denas

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Expert Opinion on Drug Safety|September 30, 2024
The safety of available pharmacotherapy for stroke prevention in atrial fibrillationG Denas, G Santostasi, V Pengo
International Journal of Cardiology|September 18, 2023
ISCHEMIC STROKE AND MAJOR BLEEDING WHILE ON DIRECT ORAL ANTICOAGULANTS IN NAÏVE PATIENTS WITH ATRIAL FIBRILLATION: IMPACT OF RESUMPTION OR DISCONTINUATION OF ANTICOAGULANT TREATMENT. A population-based studyN Gennaro, E Ferroni, M Zorzi, et al.
Platelets|March 8, 2017
The role of platelets in antiphospholipid syndromeG Baroni, A Banzato, E Bison, et al.
Lupus|April 1, 2010
Antiphospholipid syndrome: critical analysis of the diagnostic pathV Pengo, A Banzato, E Bison, et al.
Lupus|October 16, 2015
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trialV Pengo, A Banzato, E Bison, et al.
Autoimmunity Reviews|December 11, 2012
Correct laboratory approach to APS diagnosis and monitoringV Pengo, A Banzato, G Denas, et al.
Lupus|November 9, 2019
An in vitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS)E Pontara, C Cheng, M G Cattini, et al.
Lupus|May 29, 2012
Secondary prevention in thrombotic antiphospholipid syndromeV Pengo, G Denas, A Banzato, et al.
Thrombosis and Haemostasis|January 16, 2010
Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillationV Pengo, U Cucchini, G Denas, et al.
Journal of Thrombosis and Haemostasis : JTH|February 4, 2015
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at riskV Pengo, A Ruffatti, M Tonello, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Expert Opinion on Drug Safety|September 30, 2024
The safety of available pharmacotherapy for stroke prevention in atrial fibrillationG Denas, G Santostasi, V Pengo
International Journal of Cardiology|September 18, 2023
ISCHEMIC STROKE AND MAJOR BLEEDING WHILE ON DIRECT ORAL ANTICOAGULANTS IN NAÏVE PATIENTS WITH ATRIAL FIBRILLATION: IMPACT OF RESUMPTION OR DISCONTINUATION OF ANTICOAGULANT TREATMENT. A population-based studyN Gennaro, E Ferroni, M Zorzi, et al.
Platelets|March 8, 2017
The role of platelets in antiphospholipid syndromeG Baroni, A Banzato, E Bison, et al.
Lupus|April 1, 2010
Antiphospholipid syndrome: critical analysis of the diagnostic pathV Pengo, A Banzato, E Bison, et al.
Lupus|October 16, 2015
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trialV Pengo, A Banzato, E Bison, et al.
Autoimmunity Reviews|December 11, 2012
Correct laboratory approach to APS diagnosis and monitoringV Pengo, A Banzato, G Denas, et al.
Lupus|November 9, 2019
An in vitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS)E Pontara, C Cheng, M G Cattini, et al.
Lupus|May 29, 2012
Secondary prevention in thrombotic antiphospholipid syndromeV Pengo, G Denas, A Banzato, et al.
Thrombosis and Haemostasis|January 16, 2010
Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillationV Pengo, U Cucchini, G Denas, et al.
Journal of Thrombosis and Haemostasis : JTH|February 4, 2015
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at riskV Pengo, A Ruffatti, M Tonello, et al.
Pageof 3